Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

In the realm of pharmaceutical patent litigation, settlement agreements between branded and generic pharmaceutical companies are frequently used to resolve disputes before, during, and after trials in ...

Social proof, the behavioral science concept where people look to others for guidance in uncertain situations, plays a critical role in how patients decide whether to join a study. When patients hear ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and new drug development, writes Mike Banville, CEO and President at ALZpath.

There are lots of reasons why physicians and patients (and payers) might prefer one drug over another for the treatment of a given disease. Efficacy and safety are paramount, of course, but there are ...

The traditional boundaries between consumer wellness and healthcare are rapidly dissolving. This convergence is creating unprecedented opportunities for innovation, while fundamentally changing how ...

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...

They say the mark of intelligence is making the complex simple. By that standard, navigating early commercialization in the pharmaceutical industry is one of the toughest challenges, especially for ...

Electronic Clinical Outcome Assessments (eCOAs) have advanced considerably, yet persistent myths still prevent clinical teams from leveraging their full value. As regulatory expectations evolve and ...